Can US Contract Manufacturers Rely on a Phosphatidylserine Supplier COA?

US supplement contract manufacturers often ask the same question once a phosphatidylserine project moves from quoting into incoming approval: is the supplier's certificate of analysis enough, or do we still need our own identity and qualification controls?

The short commercial answer is no, the COA alone is not enough if the phosphatidylserine is being used as a dietary ingredient in US supplement manufacturing. Under 21 CFR Part 111, a manufacturer must establish component specifications, conduct at least one appropriate test or examination to verify the identity of a dietary ingredient before use unless FDA grants an exemption, and only rely on a supplier COA for other component specifications after the supplier has been qualified and that COA reliability is periodically reconfirmed. In practical buyer language, that means the COA can be part of the approval file, but it is not the whole approval file.

This matters because phosphatidylserine projects are often split across several parties. One company imports the ingredient, another stores it, and the contract manufacturer reviews the technical file. If those handoffs are not clear, teams fall back on one phrase that causes trouble later: "the supplier already sent the COA."

This article is written for US contract manufacturers, private-label supplement brands, ingredient importers, procurement managers, QA teams, and regulatory reviewers working with phosphatidylserine. It focuses on supplier qualification, identity testing, document control, and incoming release logic. It does not provide legal advice and it does not make medical treatment claims.

Where Nutranexa is mentioned, only verified site facts are used. The current site identifies the operating company as Shandong Baianrui Biopharmaceutical Co., Ltd., founded in 2013, with a 110,000+ m2 campus and a primary export focus on Europe and North America. It provides separate buyer paths for Phosphatidylserine, Soja Phosphatidylserine, and Tournesol Phosphatidylserine, and it offers visible COA, specification, packaging, manufacturing, and document-request context. Final release decisions should still depend on the current controlled files for the exact route, lot, and manufacturing stage under review.

The Short Answer Buyers Need First

If a US contract manufacturer is receiving phosphatidylserine for supplement production, the clean answer is:

1. Do not treat the supplier COA as a full substitute for incoming approval.
2. Establish the component specifications your system requires under Part 111.
3. Conduct at least one appropriate identity test or examination for the dietary ingredient before use unless FDA has granted an exemption.
4. Use a supplier COA for other component specifications only after qualifying the supplier and documenting why that COA is reliable.
5. Keep the release packet tied to the same product route, lot identity, and receiving decision.

That is the operational line between a usable supplier document and a defensible manufacturing record.

Why This Question Matters in US Contract Manufacturing

Identity testing and supplier COA reliance are not the same decision

This is where many teams blur two different rules into one conversation. Under 21 CFR 111.70, manufacturers must establish specifications for components used in dietary supplements. Under 21 CFR 111.75(a)(1)(i), before using a component that is a dietary ingredient, the manufacturer must conduct at least one appropriate test or examination to verify identity unless FDA grants an exemption. Then, under 21 CFR 111.75(a)(2), the manufacturer may rely on a supplier COA for other component specifications if the COA meets the rule's conditions.

That means a phosphatidylserine COA can support the file, but it does not erase the identity-testing step for a dietary ingredient. For buyers, the practical distinction looks like this:

The buyer question here is narrower and more operational: what can we rely on, what must we still verify ourselves, and what records must exist before the lot enters production?

Imported phosphatidylserine still needs a clean handoff between importer, QA, and manufacturer

The second reason this question matters is that imported phosphatidylserine often passes through more than one legal or operational owner before blending or encapsulation starts. FDA's FSVP framework includes modified requirements for certain dietary supplement and dietary supplement component import situations under 21 CFR 1.511 and the related FDA guidance. But even where modified FSVP requirements apply, the contract manufacturer still needs a clean internal record showing what it received, what specifications apply, what testing or examination was performed, and why the lot was released.

In practice, US teams usually need clarity on four handoff questions:

• Who imported the phosphatidylserine lot?
• Which company is relying on the supplier COA, and for which specifications?
• Which company performs or controls the identity test or examination before use?
• Which lot-specific records are handed from procurement or importer to manufacturing QA?

If those answers are not clear, supplier qualification records, import records, and incoming-release records get mixed into one incomplete file.

The Five-Part Qualification Workflow

Lock the exact phosphatidylserine route and component specification first

Before reviewing the COA, fix the commercial and technical identity of the item under review. Is the project using general phosphatidylserine, a soy route, or a sunflower route? Is the file for sample qualification, first commercial order, or reorder? Which specification version is the manufacturer using as its component standard?

That first step matters because a COA only has value when it points to a defined component. If the contract manufacturer has one specification file, procurement has another, and the importer only says "PS powder," the team is trying to qualify a document before it has qualified the commercial item.

At minimum, the incoming file should show:

• product route
• supplier name
• current specification version
• intended supplement use
• lot or batch identity if assigned
• order stage and release stage

This is also where source-specific internal links matter. If the project is route-sensitive, the buyer should keep general PS, Soy PS, and Sunflower PS file paths separate rather than collapsing them into one generic ingredient folder.

Separate identity testing from supplier COA reliance

Once the route is fixed, split the incoming review into two tracks.

Track one is identity. For a dietary ingredient, the manufacturer needs at least one appropriate identity test or examination before use unless FDA has granted an exemption. Track two is the broader component specification file, where the manufacturer may rely on the supplier COA for other agreed specifications if the rule's conditions are met.

That split removes a lot of confusion. It tells procurement that the COA is important but not sufficient by itself. It tells QA that it can build a rational release workflow instead of overtesting everything. And it tells the supplier what current files the manufacturer actually needs.

The cleanest review table often looks like this:

This workflow keeps the receiving decision aligned with Part 111 instead of treating every incoming document the same way.

Qualify the supplier before you rely on the COA for other specifications

The next step is the one many teams talk about but do not document well enough: supplier qualification. Under 21 CFR 111.75, reliance on a supplier COA for other component specifications is tied to documented supplier qualification, documentation of how the supplier was qualified, and periodic reconfirmation of COA reliability. FDA's Small Entity Compliance Guide et FSVP guidance both reinforce the need for a documented system rather than an informal trust-based decision.

For phosphatidylserine buyers, the qualification file should answer:

• which supplier is being qualified
• which phosphatidylserine route is covered by that qualification
• what evidence supports reliance on the supplier's COA
• who approved the qualification decision
• when the reliability check must be revisited

This does not mean inventing unverified claims about methods, certificates, or performance. It means the manufacturer should maintain its own justification for COA reliance on certain specifications.

If the phosphatidylserine project is early-stage, this is a good place to use Quels documents les acheteurs doivent-ils demander pour les PS ingrédients ? et Phosphatidylserine Contract Manufacturer Handoff Checklist for Private Label and First Production as supporting internal references. They help define the file structure. This article answers the narrower question of what a US contract manufacturer still has to do after those files arrive.

Build one receiving and release packet around the same lot

Even a well-qualified supplier file becomes weak if the incoming lot packet is fragmented. The contract manufacturer should tie the specification, identity-testing record, supplier COA, lot reference, receiving count, and release decision together in one controlled packet.

That packet should usually include:

• the current component specification
• the supplier COA tied to the lot or current batch path
• the internal identity test or examination record
• receiving details such as drum count and lot references
• any exception or deviation note
• the release, hold, or rejection decision

This is where the distinction between qualification and traceability becomes practical. Qualification explains why the manufacturer is willing to rely on a supplier COA for certain specifications. Traceability explains which exact lot those records apply to. Buyers who want the shipment-stage control layer can connect this workflow to the existing Phosphatidylserine Lot Traceability Checklist after the incoming approval structure is in place.

Close with records and periodic reconfirmation

The last step is to close the file properly. Under 21 CFR 111.95, manufacturers must make and keep records including the specifications they establish and documentation of supplier qualification when relying on a supplier COA. For practical purchasing and QA use, that means the phosphatidylserine file should end with a short but explicit record:

• approved for use
• approved with conditions
• held pending clarification
• rejected

The same closeout should also record whether the supplier qualification remains current or whether the COA-reliance decision needs reconfirmation before the next order. This is the step that keeps a one-time document review from turning into an undocumented standing assumption.

A Mid-Process CTA for Teams Missing Current Files

If your QA or sourcing team is still asking whether the phosphatidylserine COA is "enough," pause the release and rebuild the file around the actual Part 111 decision points. Nutranexa's contact page can be used to request the current specification, COA review support, source-specific file routing, and packaging references for the exact PS route your contract manufacturer is qualifying.

The fastest requests usually include the route, order stage, intended supplement format, destination market, and whether the team needs qualification-stage files or lot-stage release support.

Common Mistakes When Teams Say the COA Is Enough

Most failures here are workflow failures, not chemistry failures.

The common mistakes are:

1. Treating the supplier COA as if it replaces identity testing for a dietary ingredient.
2. Qualifying the supplier informally but not documenting how COA reliance was justified.
3. Using one generic PS folder for soy, sunflower, and general phosphatidylserine routes.
4. Letting the importer, warehouse, and contract manufacturer each keep different pieces of the incoming packet.
5. Closing the first order without recording when COA reliability must be revisited.

These mistakes create delays because they leave QA to reconstruct the approval logic after the material has already reached the manufacturing site.

How Verified Nutranexa Facts Fit This Workflow

For buyers evaluating Nutranexa in this US contract manufacturing context, the current site provides several verified facts that support a cleaner approval workflow.

The site identifies the company as founded in 2013 with a 110,000+ m2 campus and a primary export focus on Europe and North America. It provides separate product paths for general PS, soy PS, and sunflower PS, which helps contract manufacturers and importers keep route-specific specifications and COA files separate from the beginning.

The site also provides visible specification and COA support, Qualité & R&D follow-up, manufacturing and packaging context, and a verified PS baseline of 25 kg MOQ with 25 kg net per drum. Those facts support four practical US buyer tasks:

• defining the exact component under review
• requesting current controlled files rather than relying on outdated attachments
• aligning procurement expectations with packaging reality
• building a clearer incoming file before the lot reaches release

Nutranexa also shows document-request pathways rather than implying that one public file answers every qualification question. Public evidence can start the review, but final release should still depend on the manufacturer's own controlled records for the exact route and lot.

Sources

• eCFR: 21 CFR 111.70 - What specifications must you establish?
• eCFR: 21 CFR 111.75 - What must you do to determine whether specifications are met?
• eCFR: 21 CFR 111.95 - Under this subpart E, what records must you make and keep?
• eCFR: 21 CFR 1.511 - What FSVP must I have if I am importing a food subject to certain dietary supplement CGMP requirements?
• FDA: Small Entity Compliance Guide for Dietary Supplement CGMP
• FDA: Guidance for Industry, Foreign Supplier Verification Programs for Importers of Food for Humans and Animals

FAQ

Can a US contract manufacturer rely only on a phosphatidylserine supplier COA?

No. If phosphatidylserine is being used as a dietary ingredient in supplement manufacturing, the manufacturer still needs at least one appropriate identity test or examination before use unless FDA has granted an exemption. The supplier COA may support reliance for other component specifications only after the supplier has been qualified and that reliance is documented.

Does Part 111 let a manufacturer skip all incoming testing once a supplier is qualified?

No. Supplier qualification helps support reliance on the COA for certain specifications, but it does not erase the identity-testing requirement for a dietary ingredient or the manufacturer's obligation to establish specifications and maintain records.

What records matter most in a phosphatidylserine COA-reliance file?

The most important records are the current component specification, the supplier COA, the internal identity test or examination record, documentation of supplier qualification, lot-specific receiving and release records, and the final approval or hold decision.

How should importers and contract manufacturers divide responsibilities?

They should define who imports the lot, who controls the supplier-qualification file, who performs or controls identity testing before use, and who makes the final release decision. If those roles are not documented, the approval packet usually becomes fragmented.

What should a buyer request from Nutranexa before first production?

Request the current specification, COA review support, source-specific route confirmation, packaging details, and any other controlled files your contract manufacturer needs for incoming approval and supplier qualification.

Conclusion

For US contract manufacturers, the practical answer is clear: a phosphatidylserine supplier COA is useful, but it is not the whole approval system.

The stronger workflow locks the exact route first, separates identity testing from COA reliance, documents supplier qualification, ties the incoming packet to the same lot, and closes with records that can survive QA review and future requalification. That approach reduces release friction because it answers the real Part 111 question instead of hiding it inside a generic document bundle.

For buyers evaluating Nutranexa, the current site provides a useful starting structure through source-specific PS paths, visible specification and COA support, packaging context, manufacturing proof, and contact-based follow-up. Final use decisions should still depend on the manufacturer's own controlled qualification and release records for the exact route and lot.

Étapes suivantes recommandées

• Passez en revue le Phosphatidylserine page produit.
• Comparer Soy PS et Sunflower PS.
• Vérifier preuve de fabrication et Qualité & R&D.